Cargando...
New therapies for von Willebrand disease
The management of von Willebrand disease (VWD) is based upon the dual correction of the primary hemostasis defect, due to the inherited deficiency of von Willebrand factor (VWF), and of the secondary defect of factor VIII coagulant activity (FVIII:C), due to the loss of binding and stabilization by...
Gardado en:
| Publicado en: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society of Hematology
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913470/ https://ncbi.nlm.nih.gov/pubmed/31808884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000368 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|